Best peptides for energy & stamina

MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis and has been called an "exercise mimetic" for its ability to activate AMPK pathways.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential for cellular energy production and DNA repair that declines significantly with age.

SS-31 (Elamipretide) is a mitochondria-targeted peptide that restores mitochondrial function and has been studied in clinical trials for heart failure and mitochondrial diseases.

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is considered the mildest and most selective GHRP with fewer side effects than alternatives.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to dramatically extend the half-life of natural GHRH signaling. Developed by ConjuChem Biotechnologies in the early 2000s, it exists in two distinct forms that are frequently confused: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also known as Modified GRF (1-29) or mod GRF 1-29. Understanding this distinction is essential — they share a name but have fundamentally different pharmacokinetic profiles. The DAC version uses a reactive chemical group called maleimidopropionic acid (MPA) that forms a covalent bond with serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from minutes to 5.8-8.1 days (PMID: 16352683). Native GHRH has a half-life of approximately 7 minutes, making this roughly a 1,000-fold improvement in duration. The landmark Teichman et al. trial demonstrated that a single CJC-1295 DAC injection produced dose-dependent GH increases of 2- to 10-fold sustained for 6 or more days, with IGF-I levels rising 1.5- to 3-fold for 9-11 days (PMID: 16352683). The no-DAC version (mod GRF 1-29) has four amino acid substitutions at positions 2, 8, 15, and 27 that improve stability against dipeptidylpeptidase-IV (DPP-IV) cleavage compared to native GHRH, but without albumin binding, its half-life is approximately 30 minutes. This shorter duration preserves the natural pulsatile pattern of GH release — the body's own rhythm of GH spikes followed by quiet periods — which many researchers and clinicians consider preferable to the continuous elevation produced by the DAC form. A critical finding from the Ionescu and Frohman study confirmed that even the DAC version preserves GH pulsatility: basal GH levels increased 7.5-fold, but GH pulse frequency and magnitude remained unchanged, meaning the pituitary's natural secretory rhythm was maintained rather than overridden (PMID: 17018654). This is a meaningful safety distinction from exogenous HGH, which produces flat, supraphysiologic GH levels that suppress the body's own production. CJC-1295 has never been FDA-approved for any indication. A Phase II clinical trial of the DAC version for HIV-associated lipodystrophy was halted in July 2006 after a participant died hours after his 11th injection at an Argentine study site. The cause of death was confirmed as acute myocardial infarction. The attending physician attributed the MI to pre-existing asymptomatic coronary artery disease unrelated to CJC-1295 treatment. The study enrolled 192 HIV-positive participants with significant cardiovascular risk factors, and ConjuChem eventually went bankrupt without completing the trial. The FDA flagged cardiac concerns when reviewing CJC-1295 during the 2024 PCAC process, indicating the regulatory signal was not fully dismissed. This remains the only reported fatality associated with CJC-1295. CJC-1295 was placed on the FDA Category 2 bulk drug substance list in late 2023, effectively prohibiting compounding pharmacies from preparing it. In September 2024, the FDA referred it to the Pharmacy Compounding Advisory Committee (PCAC), which flagged cardiac side effects and immunogenicity concerns. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding status, though the specific list has not been officially published and CJC-1295's inclusion remains uncertain due to its cardiac flagging. CJC-1295 is prohibited at all times by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics.